BioCentury
ARTICLE | Financial News

Refuge raises $25M series B

May 2, 2018 2:42 PM UTC

Refuge Biotechnologies Inc. (Menlo Park, Calif.) raised $25 million in a series B round led by 3SBio Inc. (HKSE:1530) and Sequoia China. Fellow new investors Danhua Capital (DHVC), Sangel Capital and Ocean Pine Healthcare Fund also participated, as did existing investors 3E Bioventures, WuXi Healthcare Ventures and ShangBay Capital.

Co-founder and CEO Bing Wang told BioCentury that Refuge's lead candidate, RB-1916, combines CRISPR interference with a CAR T cell therapy comprising autologous T cells loaded with a lentiviral vector to conditionally inhibit PD-1. The therapy is designed to deliver dead Cas9 (dCas9) into the T cell nucleus when the CAR is attached to the B cell surface CD19 antigen. A single-guide RNA (sgRNA) delivers the dCas9 to inhibit PD-1 transcription...

BCIQ Company Profiles

Refuge Biotechnologies Inc.